Ryuichi Okamoto
Overview
Explore the profile of Ryuichi Okamoto including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
218
Citations
2731
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Osaka Y, Okamoto R, Sumi T, Koga K, Imamura H, Shirai T, et al.
J Chem Phys
. 2025 Feb;
162(5).
PMID: 39902680
Polyethylene glycol (PEG) is a widely used precipitant to concentrate proteins. The effect of PEG is generally understood to be an entropic attraction between proteins due to the depletion effect...
2.
Naganuma M, Shiga H, Shimoda M, Matsuura M, Takenaka K, Fujii T, et al.
J Gastroenterol
. 2025 Jan;
PMID: 39883201
Background: Despite the availability of several biologics for ulcerative colitis (UC), there remains a critical need to identify first-line treatment biologics. The superiority of infliximab (IFX) over vedolizumab (VED) and...
3.
Sugihara H, Okamoto R, Mizutani T
Eur J Cell Biol
. 2024 Dec;
104(1):151474.
PMID: 39740324
Organoids have revolutionized the whole field of biology with their ability to model complex three-dimensional human organs in vitro. Intestinal organoids were especially consequential as the first successful long-term culture...
4.
Takenaka K, Hisamatsu T, Kobayashi T, Yamamoto H, Ohmiya N, Hayashi R, et al.
Clin Gastroenterol Hepatol
. 2024 Dec;
PMID: 39694212
Background & Aims: Although biologic therapy has revolutionized the treatment of Crohn's disease (CD), surgery remains unavoidable in cases involving ileal complications. We aimed to evaluate the efficacy of biologics...
5.
Morikawa R, Nitta K, Yasuda S, Kano Y, Noji R, Aoyama S, et al.
Expert Opin Drug Saf
. 2024 Dec;
:1-8.
PMID: 39688366
Background: Gastrointestinal (GI) toxicities are among the most common and potentially severe immune-related adverse events (irAEs), and data on risk factors remain limited. This study aimed to identify risk factors...
6.
Takahashi J, Sugihara H, Kato S, Kawasaki S, Nagata S, Okamoto R, et al.
Cell Rep Methods
. 2024 Dec;
4(12):100930.
PMID: 39662475
Human intestinal organoids (HIOs) derived from human pluripotent stem cells (hPSCs) are promising resources for intestinal regenerative therapy as they recapitulate both endodermal and mesodermal components of the intestine. However,...
7.
Katsuda H, Kobayashi M, Ito G, Kawamoto A, Krimura S, Sato H, et al.
Endosc Int Open
. 2024 Nov;
12(11):E1379-E1385.
PMID: 39610940
Although small hypervascular tumors are suspected to be pancreatic neuroendocrine tumors (p-NENs), their diagnosis and treatment are challenging. This study evaluated the usefulness of endoscopic ultrasound-guided tissue acquisition (EUS-TA) for...
8.
Akiyama S, Shimizu H, Tamura A, Yokoyama K, Sakurai T, Kobayashi M, et al.
Aliment Pharmacol Ther
. 2024 Nov;
61(3):524-537.
PMID: 39578704
Background: Three Janus kinase (JAK) inhibitors are approved for ulcerative colitis (UC) in Japan. Aim: To compare the real-world efficacy and safety of these three JAK inhibitors in UC. Methods:...
9.
10.
Tsuchiya J, Miyoshi M, Kakinuma S, Kawai-Kitahata F, Kamiya A, Shimizu T, et al.
Cell Mol Gastroenterol Hepatol
. 2024 Oct;
19(2):101422.
PMID: 39419394
Background & Aims: Hepatitis B virus (HBV)-DNA integration into the host genome contributes to hepatocellular carcinoma (HCC) development. KMT2B is the second most frequent locus of HBV-DNA integration in HCC;...